<i<In vitro</i< antiviral activity of a double-stranded RNA sodium salt-based medicinal product against SARS-CoV-2
Scientific relevance. Innate immune activation in the early phases of COVID-19 infection and subsequent interferon induction may help control viral replication and protect cells not yet infected with SARS-CoV-2. Thus, immunostimulants that induce interferon (IFN), including double-stranded RNA-based agents, are a promising means of post-exposure prophylaxis and treatment of COVID-19 at early stages.Aim. The study evaluated the in vitro antiviral activity of a double-stranded RNA sodium salt-based medicinal product against SARS-CoV-2.Materials and methods. The authors analysed the double-stranded RNA sodium salt-based medicinal product RADAMIN®VIRO using Vero cells and the Delta variant of SARS-CoV-2 (B.1.617). The virus titre was calculated as the tissue cytopathic dose that caused 50% cell death. The authors measured the content of IFN-α and IFN-γ in the culture fluid by enzyme immunoassay and assessed the viral load by real-time polymerase chain reaction (using the cycle threshold value) and by titration (using Vero cells).Results. The studied double-stranded RNA sodium salt-based medicinal product at a concentration of 250 or 500 μg/mL induced IFN-α and IFN-γ expression by Vero cells, thus increasing their resistance to SARS-CoV-2. The authors evaluated the antiviral activity of the medicinal product based on the virus titre, viral load, and cell monolayer damage. The antiviral activity became clear 24 h after treatment, which confirmed the ability of the medicinal product to inhibit the replication of the SARS-CoV-2 virus in vitro as early as the first day after infection.Conclusions. The double-stranded RNA sodium salt-based medicinal product induced IFN-α and IFN-γ synthesis in Vero cells, increasing their resistance to SARS-CoV-2 infection in vitro. These results demonstrate the immunomodulatory and antiviral potential of the medicinal product..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Биопрепараты: Профилактика, диагностика, лечение - 23(2023), 3, Seite 290-299 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
G. M. Ignatyev [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Antiviral activity |
|---|
| doi: |
10.30895/2221-996X-2023-23-3-290-299 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ091404371 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ091404371 | ||
| 003 | DE-627 | ||
| 005 | 20240414195355.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2023 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.30895/2221-996X-2023-23-3-290-299 |2 doi | |
| 035 | |a (DE-627)DOAJ091404371 | ||
| 035 | |a (DE-599)DOAJ404627f0588842359e2ffef0a0ecda6f | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 050 | 0 | |a TP248.13-248.65 | |
| 100 | 0 | |a G. M. Ignatyev |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a <i<In vitro</i< antiviral activity of a double-stranded RNA sodium salt-based medicinal product against SARS-CoV-2 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Scientific relevance. Innate immune activation in the early phases of COVID-19 infection and subsequent interferon induction may help control viral replication and protect cells not yet infected with SARS-CoV-2. Thus, immunostimulants that induce interferon (IFN), including double-stranded RNA-based agents, are a promising means of post-exposure prophylaxis and treatment of COVID-19 at early stages.Aim. The study evaluated the in vitro antiviral activity of a double-stranded RNA sodium salt-based medicinal product against SARS-CoV-2.Materials and methods. The authors analysed the double-stranded RNA sodium salt-based medicinal product RADAMIN®VIRO using Vero cells and the Delta variant of SARS-CoV-2 (B.1.617). The virus titre was calculated as the tissue cytopathic dose that caused 50% cell death. The authors measured the content of IFN-α and IFN-γ in the culture fluid by enzyme immunoassay and assessed the viral load by real-time polymerase chain reaction (using the cycle threshold value) and by titration (using Vero cells).Results. The studied double-stranded RNA sodium salt-based medicinal product at a concentration of 250 or 500 μg/mL induced IFN-α and IFN-γ expression by Vero cells, thus increasing their resistance to SARS-CoV-2. The authors evaluated the antiviral activity of the medicinal product based on the virus titre, viral load, and cell monolayer damage. The antiviral activity became clear 24 h after treatment, which confirmed the ability of the medicinal product to inhibit the replication of the SARS-CoV-2 virus in vitro as early as the first day after infection.Conclusions. The double-stranded RNA sodium salt-based medicinal product induced IFN-α and IFN-γ synthesis in Vero cells, increasing their resistance to SARS-CoV-2 infection in vitro. These results demonstrate the immunomodulatory and antiviral potential of the medicinal product. | ||
| 650 | 4 | |a double-stranded rna sodium salt | |
| 650 | 4 | |a sars-cov-2 | |
| 650 | 4 | |a covid-19 | |
| 650 | 4 | |a antiviral activity | |
| 650 | 4 | |a interferon-α | |
| 650 | 4 | |a interferon-γ | |
| 650 | 4 | |a innate immunity | |
| 650 | 4 | |a in vitro | |
| 650 | 4 | |a vero cells | |
| 650 | 4 | |a radamin®viro | |
| 653 | 0 | |a Biotechnology | |
| 653 | 0 | |a Medicine | |
| 653 | 0 | |a R | |
| 700 | 0 | |a E. Yu. Shustova |e verfasserin |4 aut | |
| 700 | 0 | |a E. A. Rogozhina |e verfasserin |4 aut | |
| 700 | 0 | |a P. A. Belyi |e verfasserin |4 aut | |
| 700 | 0 | |a K. Ya. Zaslavskaya |e verfasserin |4 aut | |
| 700 | 0 | |a V. A. Merkulov |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Биопрепараты: Профилактика, диагностика, лечение |d Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products», 2018 |g 23(2023), 3, Seite 290-299 |w (DE-627)DOAJ000102741 |x 26191156 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:3 |g pages:290-299 |
| 856 | 4 | 0 | |u https://doi.org/10.30895/2221-996X-2023-23-3-290-299 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/404627f0588842359e2ffef0a0ecda6f |z kostenfrei |
| 856 | 4 | 0 | |u https://www.biopreparations.ru/jour/article/view/453 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2221-996X |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2619-1156 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 3 |h 290-299 | ||